Synthesis of substituted 5-bromomethyl-4-nitroimidazoles and use for the preparation of the hypoxia-selective multikinase inhibitor SN29966

Add time:07/16/2019    Source:sciencedirect.com

5-Bromomethyl-4-nitroimidazoles have utility as bioreductive trigger precursors for the preparation of hypoxia-selective prodrugs. Here we describe an efficient two-step synthesis of 5-(bromomethyl)-1-methyl-4-nitro-1H-imidazole, a preferred precursor, employing an N-bromosuccinimide mediated radical bromination. Use of this precursor to prepare SN29966, a promising hypoxia-selective irreversible pan-ErbB inhibitor is reported along with the preparation of four other prodrug candidates. 5-Bromomethyl-4-nitroimidazole analogues bearing electron-donating and electron-withdrawing substituents at the N-1 and C-2 positions are also described.

We also recommend Trading Suppliers and Manufacturers of 4-(broMoMethyl)-2-Methoxypyridine (cas 120277-15-8). Pls Click Website Link as below: cas 120277-15-8 suppliers

Prev:Spectroscopic and structural investigations of 4-bromomethyl-5-methyl-1,3-dioxol-2-one and 4,5-bis(bromomethyl)-1,3-dioxol-2-one by quantum chemical simulations – A comparative study
Next:Synthesis and antimicrobial activity of 2,3-bis(bromomethyl)quinoxaline derivatives)